NASDAQ:OMCL

Omnicell Stock Forecast, Price & News

$143.68
-1.61 (-1.11 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$142.78
$146.40
50-Day Range
$129.91
$145.29
52-Week Range
$62.24
$146.99
Volume354,691 shs
Average Volume352,299 shs
Market Capitalization$6.21 billion
P/E Ratio186.60
Dividend YieldN/A
Beta1.06
30 days | 90 days | 365 days | Advanced Chart
Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.


Omnicell logo

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.95 out of 5 stars

Medical Sector

1155th out of 2,097 stocks

Electronic Computers Industry

9th out of 13 stocks

Analyst Opinion: 1.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Omnicell (NASDAQ:OMCL) Frequently Asked Questions

Is Omnicell a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell
or view top-rated stocks.

What stocks does MarketBeat like better than Omnicell?

Wall Street analysts have given Omnicell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Omnicell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for Omnicell
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its earnings results on Thursday, April, 29th. The company reported $0.83 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.66 by $0.17. The business earned $251.84 million during the quarter, compared to analysts' expectations of $245.35 million. Omnicell had a net margin of 3.83% and a trailing twelve-month return on equity of 8.84%.
View Omnicell's earnings history
.

How has Omnicell's stock price been impacted by COVID-19 (Coronavirus)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OMCL stock has increased by 85.6% and is now trading at $143.68.
View which stocks have been most impacted by COVID-19
.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share guidance of 3.500-3.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.530. The company issued revenue guidance of $1.09 billion-$1.11 billion, compared to the consensus revenue estimate of $1.09 billion.

What price target have analysts set for OMCL?

9 brokerages have issued twelve-month price objectives for Omnicell's stock. Their forecasts range from $84.00 to $165.00. On average, they anticipate Omnicell's stock price to reach $129.25 in the next twelve months. This suggests that the stock has a possible downside of 10.0%.
View analysts' price targets for Omnicell
or view top-rated stocks among Wall Street analysts.

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 64, Pay $1.98M)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 49, Pay $963.53k)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 57, Pay $775.25k)
  • Mr. Scott Peter Seidelmann, Exec. VP & Chief Commercial Officer (Age 45, Pay $1.01M)
  • Mr. Joseph Brian Spears, Sr. VP, Chief Accounting Officer & Corp. Controller (Age 61)
  • Mr. Giri Chodavarapu, Sr. VP & Chief Information Officer
  • Ms. Kathleen Nemeth, VP of Investor Relations
  • Ms. Christine Mellon, Exec. VP & Chief People Officer
  • Mr. Jorge R. Taborga, Exec. VP of Engineering & Integration Management Officer (Age 62)
  • Ms. Diane Kaye, Sr. VP & Chief Product Officer

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.13%), Conestoga Capital Advisors LLC (3.34%), Credit Suisse AG (2.61%), Neuberger Berman Group LLC (2.13%), Geneva Capital Management LLC (2.06%) and Dimensional Fund Advisors LP (2.04%). Company insiders that own Omnicell stock include Christine Marie Mellon, Dan S Johnston, Joanne B Bauer, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell
.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Credit Suisse AG, Conestoga Capital Advisors LLC, SG Americas Securities LLC, Waddell & Reed Financial Inc., First Light Asset Management LLC, Panagora Asset Management Inc., and Peregrine Capital Management LLC. Company insiders that have sold Omnicell company stock in the last year include Peter J Kuipers, Randall A Lipps, and Robin Gene Seim.
View insider buying and selling activity for Omnicell
or view top insider-selling stocks.

Which major investors are buying Omnicell stock?

OMCL stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Victory Capital Management Inc., Oak Ridge Investments LLC, BlackRock Inc., Allianz Asset Management GmbH, Mirae Asset Global Investments Co. Ltd., Alpine Associates Management Inc., and Champlain Investment Partners LLC.
View insider buying and selling activity for Omnicell
or or view top insider-buying stocks.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $143.68.

How much money does Omnicell make?

Omnicell has a market capitalization of $6.21 billion and generates $892.21 million in revenue each year. The company earns $32.19 million in net income (profit) each year or $1.74 on an earnings per share basis.

How many employees does Omnicell have?

Omnicell employs 2,860 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

Where are Omnicell's headquarters?

Omnicell is headquartered at 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.